Corrigendum to “rotigotine Transdermal Patch in Chinese Patients with Early Parkinson's Disease: A Randomized, Double-Blind, Placebo-Controlled Pivotal Study” [park. Relat. Disord. 28 (2016) 49–55]

Zhenxin Zhang,Huifang Shang,Xingyue Hu,Shengdi Chen,Zhao Zhi-gang,Xinmiao Du,Erwin Surmann,Lars Bauer,Mahnaz Asgharnejad

DOI: https://doi.org/10.1016/j.parkreldis.2017.02.030

2017-01-01

Abstract:The authors regret that the percentage of patients receiving a Maintenance dose of 2 mg/24 h was incorrectly listed in the f‘3.3.1. Exposure’ sub-section of the ‘3. Results’ section. The correct sentence appears below; Among 122 patients treated with rotigotine in the Maintenance period, 2 (1.6%) received a Maintenance dose of 2 mg/24 h, 11 (9.0%) received 4 mg/24 h, 25 (20.5%) received 6 mg/24 h, and 84 (68.9%) received 8 mg/24 h. In ‘3.3.2. Adverse events’, there was an error in the sentence listing mild or moderate AEs. The correct sentence appears below; The maximum intensity of most AEs was considered as mild or moderate—among 71 patients experiencing AEs in the rotigotine-treated group, 94.4% experienced mild or moderate AEs, and among 63 patients experiencing AEs in the placebo-treated group, 95.2% experienced mild or moderate AEs. Reference 11 should be: C. Jenkinson, R. Fitzpatrick, V. Peto, R. Greenhall, N. Hyman, The PDQ-8: development and validation of a short-form Parkinson's disease questionnaire, Psychology and Health 12 (1997) 805–814. The authors apologise for any inconvenience caused. Rotigotine transdermal patch in Chinese patients with early Parkinson's disease: A randomized, double-blind, placebo-controlled pivotal studyParkinsonism & Related DisordersVol. 28PreviewTwo phase3 studies (SP512; SP513) involving mostly Caucasian patients showed that rotigotine (≤8 mg/24 h) was efficacious and welltolerated in early-stage Parkinson's disease (PD). We report results from a phase 3 study (SP0914/NCT01646268) investigating rotigotine in Chinese patients with early-stage PD. Full-Text PDF